Commons Sense

House of Commons · Adjournment Debate

Proscribed Psychedelic Drugs

14 March 2023 · 1 other contributor

Opened by Crispin Blunt Con Reigate

Science & TechnologyMental HealthNHS

Summarised by AI from the official record, so it can contain mistakes.

Read the full transcript on Parliament.uk

At a glance

Crispin Blunt raised concerns about proscribed psychedelic drugs in the House of Commons. A government minister responded. Other MPs also contributed.

Key points

  • The debate centres on the potential of psychedelics like psilocybin for treating mental health conditions more effectively than current treatments.
  • Crispin Blunt criticises the Misuse of Drugs Act 1971 for hindering research on psychedelics, resulting in missed opportunities over several decades.
  • Minister Chris Philp acknowledges the need for research into psychedelics and discusses ongoing efforts to review barriers to such research, including commissioning an advisory council.

How the debate unfolded

MPs spoke in turn to share their views and ask questions. Here's what each person said.

Opened the debate

Crispin Blunt Con Reigate

The debate centres on the failure of global drug policies, particularly regarding psychedelics like psilocybin. Crispin Blunt emphasises the potential of psychedelics in treating mental health conditions such as depression and post-traumatic stress disorder more effectively than current treatments. He criticises the prohibitive Misuse of Drugs Act 1971 for hindering research on these substances, leading to a significant missed opportunity over several decades. With growing evidence indicating the safety and efficacy of psychedelic-assisted therapies, Blunt calls for policy reform to facilitate access to medical treatments based on psychedelics. He also notes the substantial economic cost associated with untreated mental health issues and advocates for swift government action to support research and therapeutic use.

Other contributors (1)
  • Charlotte Nichols Lab Warrington North

    Charlotte Nichols acknowledges the issue of missed opportunities in mental health treatment due to strict drug regulations, citing personal experiences and supporting calls for evidence-based policy changes.

Government Response

Chris Philp

Minister Chris Philp acknowledges the need for research into psychedelics as medicines. He discusses ongoing efforts by his department to review barriers to such research, including commissioning an advisory council to conduct a detailed study on psychedelic drugs like psilocybin and MDMA. Philp indicates a willingness to ease regulatory requirements if evidence supports it, aiming to facilitate easier access to research materials for universities, NHS trusts, and commercial entities. He promises prompt attention to the results of this review to expedite necessary changes in policy.

Get updates like this by email
▸ Assessment & feedback
Summary accuracy